Identification and validation of UBE2B as a prognostic biomarker promoting the development of esophageal carcinomas

Han‐Fei Ding, Jiacheng Xu, Zhiguo Ding, Linfeng Wu, Yanbo Liu, Yifei Zhang, Tian‐Yin Chen, Yiqun Zhang, Ping‐Hong Zhou, Ping-Hong ZhouFrontiers in Immunology 2024 · DOI

This research paper, published in Frontiers in Immunology (February 2024), explores the role of the ubiquitination enzyme UBE2B in esophageal carcinoma. By combining large-scale bioinformatic screening with in vitro experiments, the authors identify UBE2B as a significant prognostic biomarker and a potential "oncogene" that drives tumor progression and modulates the immune microenvironment.

TL;DR

Researchers have identified UBE2B (Ubiquitin Conjugating Enzyme E2 B) as a critical driver and prognostic marker for esophageal carcinoma (ESCA). High levels of UBE2B correlate with poor patient survival and altered immune cell infiltration, while knocking down the gene significantly inhibits cancer cell growth and migration.

What Problem Does This Paper Address?

Esophageal carcinoma (ESCA) remains one of the most aggressive and deadly cancers globally, often diagnosed at late stages with limited therapeutic options. While the process of ubiquitination—a cellular "tagging" system that regulates protein degradation and signaling—is known to play a role in cancer, most research has focused on E3 ligases (the enzymes that choose the target).

The authors sought to fill a gap by investigating E2 enzymes (the "middlemen" of ubiquitination). They aimed to identify specific E2 enzymes that could serve as reliable biomarkers for predicting patient outcomes and act as novel therapeutic targets to slow tumor development.

Methods

The study employed a dual-phase approach:

  1. Bioinformatic Discovery:
    • Screening: The authors analyzed mRNA sequencing data from The Cancer Genome Atlas (TCGA). They used univariate Cox regression analysis to rank genes based on their association with overall survival (OS) in ESCA patients.
  2. Pathway Analysis: They utilized Gene Set Enrichment Analysis (GSEA), Gene Ontology (GO), and KEGG pathway analysis to determine which biological processes were linked to UBE2B expression.
  3. Immune Profiling: Using the ssGSEA algorithm, they correlated UBE2B expression with the infiltration levels of various immune cells (like T cells and macrophages).
  4. Experimental Validation:
    • Cell Lines: Experiments were conducted on two human esophageal cancer cell lines: KYSE-150 and ECA-109.
  5. Gene Silencing: The team used small interfering RNA (siRNA) to "knock down" (silence) UBE2B expression.
  6. Functional Assays: They performed CCK-8 assays (cell viability), colony formation assays, and transwell assays (migration) to see how losing UBE2B affected the cancer cells' "aggressiveness."

Datasets

  • TCGA-ESCA: Clinical and mRNA sequencing data from 163 ESCA patient samples and 11 control samples.
  • MSigDB: Used for pathway and hallmark gene set enrichment.
  • Pan-cancer data: TCGA data across multiple other cancer types to evaluate UBE2B's broader significance.

Key Insights and Ideas

  • The E2 "Middleman" Matters: While E3 ligases get most of the attention for substrate specificity, this paper highlights that the E2 enzyme UBE2B is a potent independent prognostic factor.
  • A "Hallmark" Hub: High UBE2B expression isn't just a random marker; it is statistically linked to several key drivers of malignancy, including hypoxia, the epithelial-mesenchymal transition (EMT), and TNF-α signaling via NF-κB.
  • Immune Microenvironment Modulation: Interestingly, high UBE2B expression was associated with an increase in CD8+ T cells and macrophages, but a decrease in effector memory T cells (Tem) and Th17 cells. This suggests UBE2B might play a role in shaping an immune landscape that, despite having "killer" T cells present, may be exhausted or suppressed.
  • Pan-Cancer Relevance: UBE2B isn't just an ESCA problem; the authors found it significantly upregulated and linked to poor prognosis in several other cancers, including colon, liver, and kidney carcinomas.

Key Results

  • Prognostic Power: UBE2B was identified as one of the top ten genes associated with ESCA prognosis. High expression was strongly correlated with worse overall survival ($P < 0.001$) and disease-specific survival ($P = 0.003$).
  • Diagnostic Accuracy: The ROC (Receiver Operating Characteristic) curve for UBE2B showed an AUC of 0.749, indicating it is a sensitive and specific biomarker for diagnosing ESCA.
  • Tumor Suppression via Knockdown: In the lab, silencing UBE2B led to a dramatic reduction in the number of cancer cell colonies and a significant decrease in the cells' ability to migrate through membranes ($P < 0.001$).
  • Clinical Correlation: High UBE2B expression was particularly prevalent in patients with squamous cell carcinoma (ESCC) compared to adenocarcinoma.

Limitations and Future Work

  • Sample Size: While the TCGA is a robust resource, the authors note that larger, more diverse clinical cohorts are needed to validate these findings before UBE2B can be used in a clinical setting.
  • Mechanistic Gaps: The study identifies correlations with pathways like EMT and hypoxia, but the exact molecular "handshake" (which specific proteins UBE2B ubiquitinates to cause these effects) remains to be fully mapped.
  • Lack of In Vivo Data: The current validation is limited to cell cultures (in vitro). Future studies involving animal models (xenografts) would be necessary to confirm that targeting UBE2B can actually shrink tumors in a living system.

Summary updated

Abstract

To summarize, this study has made a discovery regarding the importance of gaining new insights into the role of UBE2B in ESCA. UBE2B might be an oncogene with good ability in predicting and diagnosing ESCA. Consequently, this discovery highlights the feasibility of targeting UBE2B as a viable approach for treating patients with ESCA.
BibTeX
@inproceedings{ding2024identification,
  author = {Han‐Fei Ding and Jiacheng Xu and Zhiguo Ding and Linfeng Wu and Yanbo Liu and Yifei Zhang and Tian‐Yin Chen and Yiqun Zhang and Ping‐Hong Zhou and Yi-Qun Zhang and Ping-Hong Zhou},
  title = {{Identification and validation of UBE2B as a prognostic biomarker promoting the development of esophageal carcinomas}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1295305},
}
Figure